Clinical experience of quinupristin-dalfopristin for the treatment of antimicrobial-resistant gram-positive infections

Pharmacotherapy

Volumn 22, Issue 6 I, 2002, Pages 748-758

  Goff, Debra A ^a   Sierawski, Sondra J ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DALFOPRISTIN PLUS QUINUPRISTIN; METICILLIN; VANCOMYCIN; ANTIINFECTIVE AGENT; DRUG DERIVATIVE; QUINUPRISTIN; VIRGINIAMYCIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTEREMIA; BACTERIAL INFECTION; CLINICAL ARTICLE; DRUG EFFICACY; ENTEROCOCCUS FAECIUM; FEMALE; GRAM POSITIVE INFECTION; HOSPITAL COST; HUMAN; LENGTH OF STAY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORTALITY; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS INFECTION; COST BENEFIT ANALYSIS; MICROBIOLOGY; MIDDLE AGED; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; COST-BENEFIT ANALYSIS; DRUG RESISTANCE, MICROBIAL; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; VANCOMYCIN RESISTANCE; VIRGINIAMYCIN;

EID: 0036014879     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.22.9.748.34068     Document Type: Article

References (45)

1. Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: Project ICARE phase 2. Project intensive care antimicrobial resistance epidemiology (ICARE) hospitals
2. Antibiotic resistance in gram-positive bacteria: Epidemiological aspects
3. Antimicrobial resistance in intensive care units
4. Spread of vancomycin-resistant enterococci: Why did it happen in the United States?
5. Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada
6. Nosocomial bloodstream infections in United States hospitals: A three-year analysis
7. Surveillance of resistance against antimicrobial agents
8. Vancomycin-resistant enterococcal bacteremia: Natural history and attributable mortality
9. Quinupristin-dalfopristin: Therapeutic potential for vancomycin-resistant enterococcal infections
10. Enterococcal bacteremia in the surgical intensive care unit: Does vancomycin resistance affect mortality?
11. Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium
12. Quinupristin-dalfopristin: A review of its use in the management of serious gram-positive infections
13. RP 59500: A proposed mechanism for its bactericidal activity
14. Characterization of vancomycin-resistant Enterococcus faecium isolates from the United States and their susceptibility in vitro to dalfopristin-quinupristin
15. The efficacy and safety of quinupristin-dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium
16. Quinupristin-dalfopristin therapy for infections due to vancomycin-resistant Enterococcus faecium
17. Antibiotic-resistant gram-positive cocci: Implications for surgical practice
18. Emergence of vancomycin resistance in Staphylococcus aureus
19. Comparative safety of teicoplanin and vancomycin
20. A critical evaluation of vancomycin for treatment of bacterial meningitis
21. Antibiotics for gram-positive bacterial infections: Vancomycin, teicoplanin, quinupristin-dalfopristin and linezolid
22. Quinupristin-dalfopristin in the management of staphylococcal infections in patients failing vancomycin therapy
23. Quinupristin-dalfopristin for the treatment of staphylococcal infection in patients failing vancomycin therapy
24. Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy
25. Management of staphylococcal infections in treatment-intolerant patients: Efficacy of quinupristin-dalfopristin
26. Quinupristin-dalfopristin for the treatment of serious staphylococcal infection in vancomycin-intolerant patients
27. Successful administration of quinupristin-dalfopristin in the outpatient setting
28. Methicillin-resistant Staphylococcus aureus: Acquisition and risk of death in patients in the intensive care unit
29. Drug resistance in intensive care units
30. Control of endemic methicillin-resistant Staphylococcus aureus: A cost-benefit analysis in an intensive care unit
31. A multicenter economic analysis of bacteremia caused by methicillin-resistant Staphylococcus aureus
32. Costs of treating infections caused by methicillin-resistant staphylococci and vancomycin-resistant enterococci
33. Multivariate analysis of outcome for patients with vancomycin-resistant Enterococcus faecium (VREF) infection in the quinupristin-dalfopristin (Q/D) emergency-use program
34. Enterococcus faecium bacteremia: Does vancomycin resistance make a difference?
35. Nosocomial methicillin-resistant and methicillin-susceptible Staphylococcus aureus primary bacteremia: At what costs?
36. Economic justification of antimicrobial management programs: Implications of antimicrobial resistance
37. Pitfalls associated with commonly used methods for pharmacoeconomic analyses
38. Cost analysis of Candida infection among surgical intensive care unit patients
39. Safety and tolerability of quinupristin-dalfopristin: Administration guidelines
40. Linezolid and reversible myelosuppression
41. Hematologic effects of antimicrobials: Focus on the oxazolidinone linezolid
42. Infections due to vancomycin-resistant Entcrococcus faecium resistant to linezolid